Video

Dr. Piliè on Impact of Adiposity on Response to Androgen Signaling Inhibition in mCRPC

Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.

Patrick Pilie, MD, an assistant professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC).

Men with higher visceral adiposity, and subcutaneous adiposity, experience better responses to androgen ablative therapy, Pilie says. Additionally, although obesity and a body mass index of 26 or higher was predictive of better outcomes with this treatment, even patients who were not obese but had higher adiposity scores achieved better responses than those with lower adiposity scores, Pilie adds.

This was biologically consistent, even in the group that was not obese; thus these results demonstrate a more specific measurement of metabolic arrangements and adiposity using this imaging technique, Pilie concludes.

Related Videos
Karine Tawagi, MD,
Priya U. Kumthekar, MD
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center